echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > ASCO Amgen's innovative first-line treatment for gastric cancer reduces the risk of death by 40%

    ASCO Amgen's innovative first-line treatment for gastric cancer reduces the risk of death by 40%

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 5th, Amgen announced the latest results of its investigational anti-FGFR2b monoclonal antibody therapy bemarituzumab in a phase 2 clinical trial at the ASCO annual meeting.


    Gastric cancer is the fourth leading cause of cancer deaths in the world.


    Bemarituzumab is a monoclonal antibody against FGFR2b.


    ▲The mechanism of action of bemarituzumab (picture source: Five Prime official website)

    In this phase 2 clinical trial, the bemarituzumab combination therapy was more effective in a subgroup of patients with >10% of tumor cells overexpressing FGFR2b.


    In terms of safety, the number of adverse events in the bemarituzumab+ chemotherapy group (100%) and the chemotherapy group (98.


    Dr.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.